Mirvetuximab Soravtansine
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced High-Grade Epithelial Ovarian
Conditions
Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, Fallopian Tube Cancers, High Folate Receptor-Alpha Expression, Platinum Resistant
Trial Timeline
May 28, 2025 → Mar 1, 2028
NCT ID
NCT06682988About Mirvetuximab Soravtansine
Mirvetuximab Soravtansine is a phase 2 stage product being developed by AbbVie for Advanced High-Grade Epithelial Ovarian. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06682988. Target conditions include Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, Fallopian Tube Cancers.
What happened to similar drugs?
16 of 20 similar drugs in Advanced High-Grade Epithelial Ovarian were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06682988 | Phase 2 | Recruiting |
| NCT05041257 | Phase 2 | Completed |
Competing Products
20 competing products in Advanced High-Grade Epithelial Ovarian